ClinicalThought
Considerations When Managing HR+/HER2- Breast Cancer With CDK4/6 Inhibitors
Release Date: May 31, 2022
Expiration Date: May 30, 2023
Not certified for credit.
Begin »
Program Overview
Program Description
In this commentary, expert faculty discuss best practices for integrating CDK4/6 inhibitors into care for patients with HR+/HER2- breast cancer, including adverse event management and strategies for promoting adherence.
Format
Clinical Thought
Target Audience
NPs and PAs in oncology
Faculty
Julia LaBarbera, MSN, RN, AGACNP-BC
- Nurse Practitioner
- Division of Hematology/Oncology
- Department of Medicine
- University of California, Los Angeles
- Santa Monica, California
Details
This activity is supported by an educational grant from Lilly.
The opinions or views expressed in this CE/CME activity do not necessarily reflect the opinions or recommendations of Practicing Clinicians Exchange or any educational supporter.
Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: Biotheranostics, MJH Life Sciences.
None of the members of the Planning Committee or PCE staff have any relevant relationships to disclose.
© 2022 Practicing Clinicians Exchange. All Rights Reserved. 104922O-CT4